9001-00-7

9001-00-7 structure

Name: Bromelain
Chemical Name: Bromelain
CAS Number: 9001-00-7
Molecular Formula: C₉H₁₄N₄O₃
Molecular Weight: 226.232
Catalog: Biochemical Enzymes and coenzymes
Create Date: 2018-02-04 08:00:00
Modify Date: 2024-01-01 22:22:23
Bromelain is an anti-inflammatory drug derived from pineapple stem that acts through down-regulation of plasma kininogen, inhibition of Prostaglandin E2 expression, degradation of advanced glycation end product receptors and regulation of angiogenic biomarkers as well as antioxidant action upstream in the COX-pathway[1]. Bromelain exhibits various fibrinolytic, antiedematous, antithrombotic, and anti-inflammatory activities. Bromelain also possesses some anticancerous activities and promotes apoptotic cell death[2].

Name	Bromelain
Synonyms	2-[(3-Aminopropanoyl)amino]-3-(1H-imidazol-4-yl)propanoic acid Histidine, β-alanyl- b-Alanylhistidine β-Alanylhistidine carnosine N-(3-Aminopropanoyl)histidine EINECS 253-387-5

Description	Bromelain is an anti-inflammatory drug derived from pineapple stem that acts through down-regulation of plasma kininogen, inhibition of Prostaglandin E2 expression, degradation of advanced glycation end product receptors and regulation of angiogenic biomarkers as well as antioxidant action upstream in the COX-pathway[1]. Bromelain exhibits various fibrinolytic, antiedematous, antithrombotic, and anti-inflammatory activities. Bromelain also possesses some anticancerous activities and promotes apoptotic cell death[2].
Related Catalog	Signaling Pathways >> Apoptosis >> Apoptosis Research Areas >> Cancer
In Vivo	Bromelain (40 mg/kg; intraperitoneal injection; daily; for 7 days; male Sprague-Dawley rats) pretreatment reduces the motor dysfunction in the parkinsonian rat model of parkinson's disease (PD). 6-OHDA injection resulted in marked motor impairment which is prevented by pretreatment with Bromelain prior to the lesion[1]. Animal Model: Male Sprague-Dawley rats injected with 6-OHDA[1] Dosage: 40 mg/kg Administration: Intraperitoneal injection; daily; for 7 days Result: Reduced the motor dysfunction in the parkinsonian rat model of parkinson's disease (PD).
References	[1]. Adu TS, et al. Effects of bromelain on motor responses following intra-medial forebrain bundle 6-OHDA injection in rat model of parkinsonism. Metab Brain Dis. 2019 Jul 22. [2]. Pavan R, et al. Properties and therapeutic application of bromelain: a review. Biotechnol Res Int. 2012;2012:976203.